Skip to main content

Table 3 Immunohistochemical results for other markers

From: Periostin expression and its supposed roles in benign and malignant thyroid nodules: an immunohistochemical study of 105 cases

 

MIC

PAC

FC

PDCa

UCa

AG

FA

Gal-3

 (++)

100%

73%

0%

0%

0%

0%

0%

  (+)

0%

27%

0%

0%

100%

0%

0%

  (F+)

0%

0%

11%

50%

0%

0%

28%

  (−)

0%

0%

73%

50%

0%

100%

72%

CK19

  (++)

75%

88%

0%

0%

0%

0%

0%

  (+)

25%

61%

0%

0%

100%

0%

0%

  (F+)

0%

0%

33%

50%

0%

20%

28%

  (−)

0%

0%

67%

50%

0%

80%

72%

HBME-1

  (++)

75%

85%

0%

0%

0%

0%

0%

  (+)

17%

10%

0%

0%

0%

0%

0%

  (F+)

8%

0%

11%

50%

0%

10%

11%

  (−)

0%

5%

89%

50%

100%

90%

56%

Cyclin D1

  (++)

100%

95%

0%

0%

0%

0%

0%

  (+)

0%

0%

0%

50%

0%

0%

0%

  (F+)

0%

0%

11%

50%

100%

0%

17%

  (−)

0%

5%

89%

0%

0%

100%

83%

Ki-67 L.I. (mean percentage

 

5.2%

7.1%

3.3%

10%

65%

< 1%

2.9%

  1. *Gal-3 Galectin-3, HBME-1 Hector Battifora mesothelial-1, CK cytokeratin
  2. *MIC Microcarcinoma, PAC Papillary thyroidal carcinoma, FC Follicular carcinoma, PDCa Poorly differentiated carcinoma, UCa Undifferentiated carcinoma, AG Adenomatous goiter, FA Follicular adenoma
  3. *(−), negative [0%]; (F+), focally positive [1–9%]; (+), positive [10–49%]; (++), diffusely positive [≥50%]; L.I., labeling index